Olanzapine/fluoxetine (trade name Symbyax , made by Eli Lilly and Company) is a single capsule containing atypical antipsychotic oanzapine and selective serotonin reuptake (SSRI) fluoxetine inhibitors. Olanzapine/fluoxetine is primarily used to treat depressive episodes of bipolar I disorder as well as drug-resistant depression.
Video Olanzapine/fluoxetine
Medical use
Olanzapine/fluoxetine was approved by the US Food and Drug Administration (FDA) to treat episodes of bipolar I disorder depression in 2003. In 2009, it was approved for the treatment of drug-resistant depression.
Olanzapine/fluoxetine, or a combination of other antidepressants/antipsychotics, is sometimes prescribed for anxiety disorders, eating disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).
Maps Olanzapine/fluoxetine
Side effects
Possible side effects of olanzapine/fluoxetine include all of the two component drugs: olanzapine and fluoxetine. Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision, and difficulty concentrating.
Olanzapine/fluoxetine may produce severe allergic reactions and should not be used if the patient previously had an allergic reaction either to fluoxetine or olanzapine.
Olanzapine correlates with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring.
In rare cases, olanzapine/fluoxetine may cause neuroleptic malignant syndrome.
Like other SSRIs, olanzapine/fluoxetine carries a box warning stating that it can increase the risk of mind and behavior for suicide in patients aged 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.
See also
- Amitriptyline/perphenazine
- Aripiprazole/sertraline
- Flupentixol/melitracen
- Tranylcypromine/trifluoperazine
References
External links
- The official website of the U.S.
Source of the article : Wikipedia
0 Comments